Anatomic Location Predicts Response Rates: Real World Outcomes With Over 1100 Cycles of Talimogene Laherparepvec Description
Authors:
- 10 September 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (6) , 963-970
Abstract
Objective: We hypothesized that anatomic location of metastatic melanoma is associated with the degree of therapeutic response to talimogene laherparepvec (TVEC). Background: TVEC is the first FDA-approved injectable oncolytic virus to treat unresectable stage IIIB-IV metastatic melanoma patients. Previously published real-world outcomes demonstrated a 39% complete response (CR) rate to TVEC. Methods: A prospective single-center melanoma database of patients treated with TVEC from December 2015 to December 2023 was analyzed. Patients were categorized into groups based on treated anatomic sites. Patient characteristics were summarized using frequencies, means, medians, comparisons, and tests of proportions using χ 2 , Fisher exact, and Wilcoxon rank sum tests. We used unadjusted generalized estimating equation models with repeated measures to estimate relative risk ratios for local treatment response and anatomic sites. Results: One hundred seventy-three patients were included: median age 75 years; majority male (n = 112, 64.7%) and white (n = 170, 98.3%). We analyzed 190 therapeutic plans of TVEC with a total of 1133 cycles, median 6 cycles/patient (1 to 18). Median follow-up was 41 months (11 to 107). Of the anatomic sites treated, 73 were head/neck (38.4%), 73 lower extremity (38.4%), 25 torso (13.2%), and 19 upper extremity (10%). CR was seen in 79 (41.6%), partial response (PR) in 41 (21.6%), mixed response/stable disease in 37 (19.5%), and disease progression in 33 (17.4%). In the CR group, 40 (50.6%) responses were head/neck, 24 (30.4%) lower extremity, 11 (13.9%) torso, and 4 (5.1%) upper extremity. Conclusions: This is the largest prospective cohort evaluating real-world outcomes of metastatic melanoma patients treated with TVEC based on anatomic location. TVEC is a well-tolerated, durable treatment for advanced-stage melanoma. Our findings demonstrate head/neck metastases have the greatest CR rate and should be considered as a possible first-line therapy in select patients.Keywords
This publication has 24 references indexed in Scilit:
- Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary ExperienceCardioVascular and Interventional Radiology, 2021
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional ExperienceJournal of the American College of Surgeons, 2019
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single InstitutionJournal of the American College of Surgeons, 2011
- Intra‐lesional interleukin‐2 for the treatment of in‐transit melanomaJournal of Surgical Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusionSeminars in Surgical Oncology, 1998
- Intralesional BCG in the treatment of metastatic malignant melanomaCancer, 1976